Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Michael B Hoffman is Director at Annovis Bio. OQRO lists 20 transactions filed with the SEC under this name, the latest on Nov 6, 2026, each linked to the official Form 4.
Director
Disclosures on record
20
Companies involved
1
7 buys, median −32.6 pts vs S&P 500, beat it 1 of 7 times.
Average −30.9 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 12, 2025 to May 22, 2026, measured from the first close after the filing. Past results, not a forecast.
8 purchases disclosed; 14% of the 7 measured at 90 days finished ahead of the index. $1,000 placed after each of the 7 purchases disclosed since 2025-11-14 would be worth $2.8K today ($7K put in); the same in the S&P 500 (SPY): $7.6K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Annovis BioANVS
20 disclosures · Nov 2025 – Nov 2026 · 19 bought
Nov 6, 2026Bought~$5M
DetailsOfficial recordNov 6, 20265M
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
May 20, 2026Bought~$104Kdisclosed May 22
DetailsOfficial recordMay 20, 2026Bought~$34Kdisclosed May 22
DetailsOfficial recordMay 20, 2026Bought~$4.5Kdisclosed May 22
DetailsOfficial recordApr 2, 2026Bought~$1.5Mdisclosed Apr 3
DetailsOfficial recordDec 8, 2025Bought~$130Kdisclosed Dec 9
DetailsOfficial recordDec 8, 2025Bought~$64Kdisclosed Dec 9
DetailsOfficial recordNov 24, 2025Bought~$117Kdisclosed Nov 25
DetailsOfficial recordNov 24, 2025Bought~$117Kdisclosed Nov 25
DetailsOfficial recordNov 24, 2025Bought~$35Kdisclosed Nov 25
DetailsOfficial recordNov 24, 2025Bought~$35Kdisclosed Nov 25
DetailsOfficial recordNov 24, 2025Bought~$1.7Kdisclosed Nov 25
DetailsOfficial recordNov 24, 2025Bought~$6.1Kdisclosed Nov 25
DetailsOfficial recordNov 24, 2025Bought~$6.1Kdisclosed Nov 25
DetailsOfficial recordNov 24, 2025Bought~$1.7Kdisclosed Nov 25
DetailsOfficial recordNov 21, 2025Bought~$35Kdisclosed Nov 22
DetailsOfficial recordNov 21, 2025Bought~$35Kdisclosed Nov 22
DetailsOfficial recordNov 14, 2025Bought~$32Kdisclosed Nov 18
DetailsOfficial recordOct 28, 2025Bought~$2Mdisclosed Nov 12
DetailsOfficial recordAs of the latest filing on , Michael B Hoffman reported holding 8,364,883 shares of Annovis Bio (ANVS), worth about $7.75M at the last close of $1 (Nov 13, 2026). In the last 12 months, Michael B Hoffman bought $7.26M in 18 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Annovis Bio ANVS | 8,364,883 | 8.36M direct | $1 | $7.75M | Nov 6, 2026 |
Is this Michael B Hoffman’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Michael B Hoffman bought shares on the open market in 2013, 2014, 2018, 2020, 2025 and 2026 across 2 companies. Sales in 2 of the 14 years since 2013.
Michael B Hoffman reported 33 open-market purchases and 6 sales since 2013; purchases in 6 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $6.64M5×5 trades | — |
| 2025 | $2.62M14×14 trades | — |
| 2020 | $200K1×1 trade | $50K2×2 trades |
| 2018 | —1×1 trade | $45K4×4 trades |
| 2014 | $1.9M4×4 trades | — |
| 2013 | $15.4M8×8 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 6, 2026, Michael B Hoffman reported holding 8,364,883 shares of Annovis Bio (ANVS). At the last close of $1 on Nov 13, 2026, that is about $7.75M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Michael B Hoffman reported 18 open-market purchases worth $7.26M, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Michael B Hoffman bought shares on the open market in 2013, 2014, 2018, 2020, 2025 and 2026 across 2 companies. Sales in 2 of the 14 years since 2013.
In SEC filings since 2013: the latest open-market purchase is from 2026; the latest open-market sale is from 2020.
2 companies: Annovis Bio (ANVS, 2020–2026), Traws Pharma (TRAW, 2013–2020).
Michael B Hoffman reported 20 open-market purchases and 0 sales here, 2020 to 2026.
Michael B Hoffman reported 13 open-market purchases and 6 sales here, 2013 to 2020.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
